BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36648496)

  • 1. Recent progress in nanomedicines for imaging and therapy of brain tumors.
    Hasan I; Roy S; Guo B; Du S; Tao W; Chang C
    Biomater Sci; 2023 Feb; 11(4):1270-1310. PubMed ID: 36648496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect.
    Zhang S; Zhang S; Luo S; Tang P; Wan M; Wu D; Gao W
    J Nanobiotechnology; 2022 Jun; 20(1):287. PubMed ID: 35710426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics.
    Tang W; Fan W; Lau J; Deng L; Shen Z; Chen X
    Chem Soc Rev; 2019 Jun; 48(11):2967-3014. PubMed ID: 31089607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent nano delivery systems for selective imaging and treatment of brain tumors.
    Ljubimova JY; Sun T; Mashouf L; Ljubimov AV; Israel LL; Ljubimov VA; Falahatian V; Holler E
    Adv Drug Deliv Rev; 2017 Apr; 113():177-200. PubMed ID: 28606739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silica nanoparticles for brain cancer.
    Feng Y; Cao Y; Singh R; Janjua TI; Popat A
    Expert Opin Drug Deliv; 2023; 20(12):1749-1767. PubMed ID: 37905998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A state-of-the-art liposome technology for glioblastoma treatment.
    Hasan I; Roy S; Ehexige E; Wu R; Chen Y; Gao Z; Guo B; Chang C
    Nanoscale; 2023 Nov; 15(45):18108-18138. PubMed ID: 37937394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.
    Brighi C; Reid L; Genovesi LA; Kojic M; Millar A; Bruce Z; White AL; Day BW; Rose S; Whittaker AK; Puttick S
    Theranostics; 2020; 10(14):6361-6371. PubMed ID: 32483457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comprehensive Review on Nanomedicine: Promising Approach for Treatment of Brain Tumor through Intranasal Administration.
    Bahadur S; Prakash A
    Curr Drug Targets; 2023; 24(1):71-88. PubMed ID: 36278468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption.
    Janowicz PW; Houston ZH; Bunt J; Fletcher NL; Bell CA; Cowin G; Howard CB; Taslima D; Westra van Holthe N; Prior A; Soh V; Ghosh S; Humphries J; Huda P; Mahler SM; Richards LJ; Thurecht KJ
    Biomaterials; 2022 Apr; 283():121416. PubMed ID: 35217483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane-encapsulated camouflaged nanomedicines in drug delivery.
    Ghosh S; Girigoswami K; Girigoswami A
    Nanomedicine (Lond); 2019 Aug; 14(15):2067-2082. PubMed ID: 31355709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patented nanomedicines for the treatment of brain tumors.
    Caruso G; Raudino G; Caffo M
    Pharm Pat Anal; 2013 Nov; 2(6):745-54. PubMed ID: 24237240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier.
    Omidi Y; Kianinejad N; Kwon Y; Omidian H
    Expert Rev Clin Pharmacol; 2021 Mar; 14(3):357-381. PubMed ID: 33554678
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancements in nanotherapeutics for Alzheimer's disease: current perspectives.
    Harilal S; Jose J; Parambi DGT; Kumar R; Mathew GE; Uddin MS; Kim H; Mathew B
    J Pharm Pharmacol; 2019 Sep; 71(9):1370-1383. PubMed ID: 31304982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
    Tam VH; Sosa C; Liu R; Yao N; Priestley RD
    Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.